[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rtms-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rtms-stimulation":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,80,102,129,153,183,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100598420","study-of-the-correlation-between-cortical-excitability-and-cytoarchitectonics-of-prefrontal-cortex-in-healthy-adult-participants-using-transcranial-magnetic-stimulation-coupled-to-eeg-and-high-field-mri-100598420",false,"NCT07071259","Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI","FrontalProbe","Inclusion Criteria:\n\n* People aged 18 to 35\n* People affiliated with a social security scheme or beneficiary of such a scheme\n* People who have signed the informed consent\n* Right-handed people\n* People with a body mass index between 18 and 26\n* People able to abstain from alcohol for 24 hours prior to the experiment\n* People able to remain perfectly still for 15 minutes straight, and able to have reduced mobility for 3 hours\n* People able to of not using narcotics (marijuana, cocaine, ecstasy, MDMA, ketamine, etc.) during the 15 days preceeding the experiment.\n* Conducting a pregnancy test before inclusion for women of childbearing age and when the research is conducted over a long period, at a frequency adapted to the gaze of the research acts\n* Effective contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Pregnant, parturient, or breastfeeding\n* Protected adults\n* Minors\n* People staying in a healthcare or social institution\n* People in an emergency situation\n* People deprived of their liberty\n* People with the usual contraindications to MRI\n\n  * Ferromagnetic surgical clips, ocular implants, metallic foreign bodies intraocularly or in the nervous system, implants or metallic objects susceptible to concentrate the radio frequency field, cochlear implants, brain stimulator or cardiac pacemaker, presence of a craniotomy scar, agitation\n  * Claustrophobia\n  * Large, black tattoo close to the orofacial area\n* People not wishing to be informed of abnormalities discovered at the MRI\n* People with a history of epilepsy or suffering from epilepsy\n* Individuals whose parents, children, siblings, or parents have a history of epilepsy\n* People with known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Staff with a hierarchical link to the investigators",true,"ALL","18 Years","35 Years",{"count":21,"type":22},34,"ESTIMATED","INTERVENTIONAL",[25],"NA","Repeated transcranial magnetic stimulation (rTMS) is mainly used to treat mood disorders by addressing differences in brain function, particularly in the dorsolateral prefrontal cortex (DLPFC), which affects emotions and executive functions. The therapy aims to enhance the left DLPFC or suppress the right. It has been approved for severe major depression in several countries (Canada and Israel since 2002, USA since 2008) and is in the process of being validated in Europe but is not yet reimbursed in France. due to variable results from one study to another and lack of standardization issues.\n\nIn a previous study, by recording electroencephalographic (EEG) rhythms before and after rTMS treatment of the DLPFC, the investigators showed on a small cohort of patients (n=17) with major or bipolar depression, that the responder patients showed higher EEG theta rhythms in the DLPFC but also and especially in parietal regions. This suggests that the DLPFC is part of the fronto-parietal central executive network (CEN), which is important for working memory and cognitive control. The CEN is not well connected in severe resistant depression, possibly leading to negative emotional bias. The rTMS cure of DLPFC can be interpreted as improving depressive symptoms through the normalization of the CEN by increasing DLPFC excitability and its downward connectivity. However experimental and clinical evidence for this mechanism, among others, is still to be demonstrated, and remission rates of rTMS from DLPFC in drug-resistant depression are still low (20-40%).\n\nTo improve these response rates to rTMS in DLPFC, it is essential to continue research aimed at improving clinical practices through a better knowledge of the functional neuroanatomy and mechanisms of action of rTMS. This will require the definition of biomarkers allowing in particular to better target the DLPFC, this structure beeing indeed relatively poorly defined on the neuroanatomical level (large portion of the medial frontal gyrus). To this end, the investigators have set up a collaborative research program with Dr. Corey Keller, psychiatrist at Stanford University USA, which was jointly funded in 2022 by the Agence Nationale pour la Recherche (ANR) and the National Institute of Health (NIH) - FrontalProbe project \"Probing the dorsolateral prefrontal cortex and central executive network for improving neuromodulation in depression\". The ultimate aim of this project is to develop and test different strategies for targeting the DLPFC in the rTMS treatment of pharmaco-resistant depressive patients, following the fundamental neuroanatomical and pathophysiological hypothesis that patients will respond better to therapy if their CEN network is better modulated. This clinical trial will take place in Stanford, USA, in the years 2025-2026. Previously, the investigators are working on the development of methodological strategies aimed at preferentially activating, in a personalized way, the part of the DLPFC that projects onto the PPC. This is the subject of the present protocol, which aims to identify this subpart of the DLPFC to be targeted as a priority for modulating the CEN, through neuroanatomical measurements with high-field MRI and cortical excitability by TMS-EEG in healthy subjects. To this end, the investigators will use a small cohort of healthy subjects who will have one multimodal MRI acquisition session of at 7T and one TMS-EEG session. The 7T MRI data, acquired at the Centre de Résonance Magnétique en Biologie et Médecine (CRMBM), will be used to obtain anatomical markers of the DLPFC. TMS-EEG data, acquired at the Institut de Neurosciences de Systèmes (INS), will be used for cortical excitability measurements of the DLPFC and its projection sites, notably the PPC. At this stage, no data exchange is planned with our American partners.\n\nFirstly, the processing of MRI data will include segmentation of gray and white matter, reconstruction of the cortical surface and estimation of the different cortical layers, mainly by monitoring variations in the T1 parameter along the cortical mantle. Other MRI parameters will also be acquired to maximize the specificity of the segmentation of the DLPFC into sub-regions, firstly by identifying the part of the DLPFC that connects preferentially to the PPC using the reconstruction of fiber bundles from diffusion MRI and functional resting MRI. Secondly, during TMS-EEG acquisitions, participants will be stimulated in 3 sub-regions of the DLPFC. For each target, the analyses of the EEG data will focus on quantifying connectivity with the PPC as well as their spectral signature, which is possibly an indirect reflection of the neuronal composition of the stimulated regions.\n\nCorrelation of 7T MRI and TMS-EEG data will help set optimal DLPFC targeting criteria for PPC activation. The aim is to create an MRI-based targeting procedure for clinical practice. In this sense, TMS-EEG will serve as validation of MRI markers.",[28,29,30,31,32,33],"Healthy Participants","Magnetic Stimulation","MRI","EEG","Dorsolateral Prefrontal Cortex","rTMS Stimulation","NOT_YET_RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":22},"2026-07-15",{"date":42,"type":22},"2028-04",{"name":44,"class":45},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100580283","novel-brain-stimulation-treatment-for-neuropsychiatric-symptoms-in-alzheimers-disease-100580283","NCT06835283","Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease","Sequential Accelerated ITBS \u002F Remote tDCS for Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease: A Pilot Study","Inclusion criteria\n\n1. veteran between the ages of 60 to 85\n2. clinical diagnosis of mild to moderate Alzheimer's disease or related dementia\n3. clinically significant neuropsychiatric symptoms (NPS) evidenced by a score ≥ 2 in at least one domain of the Neuropsychiatric Inventory Questionnaire\n4. mild to moderate cognitive impairment demonstrated by a Mini-Mental State Examination (MMSE) score of 15-23\n5. have a caregiver who is able and willing to escort the patient to\u002Ffrom clinic visits, answer questionnaires, and assist in the implementation of treatment sessions at home\n6. if taking psychotropic medications, demonstrate stability for at least 4 weeks of treatment\n\nExclusion Criteria:\n\n1. any contraindication for MRI\n2. any contraindication for iTBS\u002FtDCS including but not limited to seizure disorder, severe cardiovascular disease, history of brain surgery, or stroke involving the cerebral cortex near area of stimulation\n3. current alcohol or substance use disorder determined by QuickSCID (nicotine allowed; mild cannabis and alcohol use is allowed)\n4. neuropsychiatric symptoms (NPS) that are severe enough to preclude the intervention from being delivered safely and effectively, particularly agitation or aggression.\n\n6\\) any unstable coexisting medical condition that in the opinion of the principal investigator(s) interferes with the treatment protocol or increase the likelihood of adverse events.","65 Years","85 Years",{"count":57,"type":22},20,[25],"The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explore whether the combined treatment shows promise for reducing neuropsychiatric symptoms like mood swings, apathy, and agitation, and will evaluate the impact of the treatment on caregivers.\n\nThe main questions the study aims to answer are:\n\n1. Is the combined brain stimulation treatment practical and well-tolerated?\n2. Do preliminary results suggest that this treatment could help manage neuropsychiatric symptoms and support a larger study?\n\nParticipants will:\n\n* Attend nine in-person visits over three months.\n* Complete one week of in-clinic brain stimulation sessions (iTBS) followed by four weeks of daily at-home brain stimulation sessions (tDCS).\n* Take part in brain scans, questionnaires, and brain activity tests before and after the treatment.\n\nThis pilot study is a first step to assess whether this combined treatment approach is practical and whether it has potential to improve symptoms, laying the groundwork for larger studies in the future.",[61,62,33],"Alzheimer&Amp;#39;s Disease-related Dementia","Alzheimer Disease",[64,65,66,67,68],"Alzheimer's Disease","tDCS","iTBS","brain stimulation","mood swings","RECRUITING","2026-05-05",{"date":72,"type":38},"2026-05-07",{"date":74,"type":22},"2026-08-01",{"date":76,"type":22},"2027-08",{"name":78,"class":79},"Baylor College of Medicine","OTHER",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100619605","the-underlying-neural-mechanism-of-tms-in-improving-the-imbalance-of-microbiota-brain-gut-axis-in-alzheimer-s-disease-population-100619605","NCT07346794","The Underlying Neural Mechanism of TMS in Improving the Imbalance of \"Microbiota-brain-gut Axis\" in Alzheimer 's Disease Population","Inclusion Criteria:\n\n* Dementia Patients: Conformed to internationally recognized diagnostic criteria for dementia (e.g., DSM-5, NINCDS-ADRDA)\n* Diagnosed through clinical evaluation, neuropsychological scale assessments, and relevant examinations\n* Aged ≥50 years and residing in Nanchang, Jiangxi\n* With dementia-negative family history, no severe psychiatric or neurological disorders\n* No history of major systemic diseases.\n\nExclusion Criteria:\n\n* Unable to cooperate with all required examinations, intervention procedures, and sample collection during the study.","50 Years",{"count":88,"type":22},400,[25],"What is this study about? This study focuses on Alzheimer's Disease (AD), a common neurodegenerative disease that affects memory, thinking, and daily life. We aim to explore whether a non-invasive treatment called Repetitive Transcranial Magnetic Stimulation (rTMS) can improve AD symptoms by regulating the \"gut-brain-intestine axis\" - a connection between gut bacteria, the brain, and the intestines.\n\nWho can participate?\n\n* \\*\\*AD patients\\*\\*: Aged 50-80, diagnosed with mild to moderate AD (MMSE score 18-27, MoCA score 10-26), with stable condition for at least 6 months, and able to cooperate with tests and treatment.\n* \\*\\*Healthy controls\\*\\*: Aged 50-80, with normal cognitive function (MMSE ≥28, MoCA ≥27), no AD family history, and matched in age and gender with AD patients.\n\nThose with epilepsy, severe mental illness, recent use of antibiotics\u002Fprobiotics, or inability to complete MRI scans are not eligible.\n\nWhat will participants experience?\n\n* \\*\\*AD patients\\*\\*: Will be randomly divided into two groups. Both groups will receive 4 weeks of treatment (5 days\u002Fweek) with a helmet-like device. One group gets real rTMS (safe magnetic stimulation to the brain), and the other gets sham stimulation (no effective magnetic field, but same sound\u002Ffeel).\n* \\*\\*Healthy controls\\*\\*: No treatment, but will complete the same tests as AD patients.\n* \\*\\*Tests during the study\\*\\*: Cognitive assessments (memory, thinking skills via questionnaires), stool\u002Fblood sample collection (to check gut bacteria and body markers), and MRI scans (to look at brain structure\u002Ffunction) at baseline, 1 month, 3 months, 6 months, and 1 year.\n\nWhat are the potential benefits?\n\n* Free rTMS treatment (for AD patients), free MRI scans (valued at 700 RMB), and a 200 RMB subsidy.\n* Free health checks (gut bacteria analysis, metabolic tests) and cognitive evaluations to understand personal health status.\n* Contribution to developing new AD treatments that may help future patients.\n\nIs it safe? rTMS is a clinically proven safe technique. Possible mild side effects (headache, scalp irritation) usually go away on their own. Sample collection (stool\u002Fblood) and MRI scans are non-invasive or minimally invasive. A professional team will monitor participants throughout to handle any issues.\n\nFor healthcare providers This is a multicenter, randomized, double-blind sham-controlled study (200 AD patients, 200 healthy controls). The primary goal is to explore rTMS's mechanism via the gut-brain-intestine axis, with MoCA score changes (6 months post-treatment) as the main outcome. It integrates multi-omics and neuroimaging data to provide evidence for AD's non-drug treatment.",[92,33],"Alzheimer's Disease","2026-04-04",{"date":95,"type":38},"2026-04-09",{"date":97,"type":22},"2026-04-21",{"date":99,"type":22},"2030-09-30",{"name":101,"class":79},"Second Affiliated Hospital of Nanchang University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":46},"100608114","repetitive-transcranial-magnetic-stimulation-primed-self-controlled-practice-on-motor-learning-100608114","NCT07197346","Repetitive Transcranial Magnetic Stimulation Primed Self-controlled Practice on Motor Learning","The Effects of Repetitive Transcranial Magnetic Stimulation Primed Self-controlled Practice on Motor Learning and Motivation","Inclusion Criteria:\n\n1. Healthy adults aged 18-35 years\n2. Right-handed (per Edinburgh Handedness Inventory)\n3. Normal or corrected-to-normal vision and hearing\n4. Eligible for non-invasive brain stimulation per safety screening (no contraindications to TMS)\n5. Able to understand study procedures and provide written informed consent in Chinese\n6. Willing to comply with all study visits and tasks, including TBS\u002FrTMS and motor practice\n7. For yoked pairing: able to be matched to a counterpart participant for practice parameters\n\nExclusion Criteria:\n\n1. History of epilepsy, seizures, or unexplained fainting; family history of epilepsy in first-degree relatives\n2. Any intracranial metal or implanted medical devices (e.g., cochlear implant, deep brain stimulator, aneurysm clips); non-removable metallic objects in head\u002Fneck\n3. Cardiac pacemaker or other implanted electronic devices\n4. Current or past major neurological or psychiatric disorders (e.g., stroke, traumatic brain injury, multiple sclerosis, major depression, bipolar disorder, schizophrenia)\n5. Current use of medications lowering seizure threshold or affecting cortical excitability (e.g., tricyclic antidepressants, bupropion, clozapine, lithium, stimulant or sedative-hypnotic abuse); or unstable psychotropic regimens\n6. Active migraine with aura or chronic severe headaches\n7. Pregnancy or planning pregnancy during participation; breastfeeding (if your site policy excludes)\n8. Substance or alcohol use disorder within the past 12 months; positive alcohol\u002Fdrug screen on visit days\n9. Sleep deprivation (\\\u003C5 hours) on the day before stimulation, or excessive caffeine (\\>400 mg) within 6 hours pre-stimulation\n10. Dermatologic conditions or open wounds at stimulation or EMG\u002Felectrode sites\n11. Prior extensive training on the specific motor task used in this study (risk of ceiling effects)\n12. Concurrent participation in another interventional study or received brain stimulation (TMS\u002FtDCS) within the past 3 months\n13. Any condition that, in the investigator's judgment, makes participation unsafe or data unreliable",{"count":110,"type":22},72,[25],"This study aims to investigate the additive effects of combining self-controlled practice with repetitive transcranial magnetic stimulation (rTMS) pretreatment on motivation enhancement and motor learning performance in healthy young adults. According to the \"Optimizing Performance Through Intrinsic Motivation and Attention for Learning\" (OPTIMAL) theory, numerous studies have demonstrated that providing learners with autonomy during practice can facilitate intrinsic motivation and motor learning. However, self-controlled practice alone may have limited effects, and further interventions may be required to amplify learning outcomes.\n\nIn recent years, non-invasive brain stimulation techniques-particularly high-frequency (facilitatory) rTMS applied to the dorsolateral prefrontal cortex (DLPFC)-have been shown to enhance motivational drive and explicit learning performance by strengthening the connectivity of the DLPFC-midbrain dopamine pathway. For example, 10 Hz high-frequency stimulation can significantly improve learners' accuracy and motivation. Interestingly, several sequence learning studies have found that low-frequency (inhibitory) rTMS, when used as a priming intervention, can instead enhance implicit procedural learning. This effect may occur because inhibiting the lateral prefrontal cortex reduces its top-down suppression of implicit learning systems, thereby releasing procedural learning potential.\n\nBased on the theory of metaplasticity, applying facilitatory or inhibitory stimulation beforehand can alter the threshold of synaptic plasticity, thus influencing subsequent learning outcomes. Therefore, this study designed two DLPFC pretreatments-facilitatory and inhibitory-and combined them with self-controlled practice to systematically examine the interaction between different stimulation protocols on motivation and motor learning.\n\nThis cross-sectional experiment plans to recruit 72 healthy participants aged 20 or older, randomly assigned to one of six groups: (1) facilitatory rTMS + self-controlled practice, (2) facilitatory rTMS + yoked control, (3) inhibitory rTMS + self-controlled practice, (4) inhibitory rTMS + yoked control, (5) sham rTMS + self-controlled practice, and (6) sham rTMS + yoked control.\n\nThe experiment will last for seven days. On Day 1, participants will complete baseline testing, followed by facilitatory rTMS, inhibitory rTMS, or sham stimulation over the DLPFC. Immediately afterward, they will engage in a trajectory-tracking learning task (manipulating a joystick to reproduce a sine-wave pattern). After practice, participants will complete a motivation assessment. During the trajectory-tracking task, the self-controlled group can choose when to receive feedback to adjust their learning, whereas the yoked control group will receive feedback at time points matched to their paired counterpart.\n\nOn Day 2, participants will again receive the assigned rTMS (facilitatory, inhibitory, or sham), complete the trajectory-tracking task, and undergo a motivation assessment. After a five-minute rest, they will perform retention and transfer tests, followed by TMS measurement of cortical excitability. On Day 7, participants will return to the laboratory to complete another retention and transfer test, along with cortical excitability measurement via TMS.\n\nThe primary behavioral outcomes are the root mean square error (RMSE) and error estimation (EE) in the trajectory-tracking task. Motivation will be assessed using the Intrinsic Motivation Inventory (IMI). As there have been no prior studies combining DLPFC rTMS pretreatment with practice autonomy, the results of this experimental design are expected to provide new insights and references for enhancing motor learning ability in healthy adults.",[33,114,115],"Autonomy","Healthy Young Adults",[117,118,119],"motor learning","repetitive transcranial magnetic stimulation","autonomy","2025-09-22",{"date":122,"type":38},"2025-09-29",{"date":124,"type":38},"2025-09-01",{"date":126,"type":22},"2028-12-31",{"name":128,"class":79},"National Taiwan University Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":46},"100599222","efficacy-of-non-invasive-neuromodulation-on-pain-in-migraine-100599222","NCT07081685","Efficacy of Non-Invasive Neuromodulation on Pain in Migraine","ENDIM","Inclusion criteria :\n\n* Age greater than or equal to 18 years ;\n* Frequent episodic or chronic migraine: migraine more than 8 days per month for more than 3 months;\n* Maximum 26 headache days \u002F 28 ;\n* Failure (ineffectiveness, intolerance or contraindication) to at least 3 background drug treatments;\n* Analgesic treatment stable for at least one month and will not need to be modified for the duration of the study;\n* Patient can be followed throughout the study;\n* Information letter read and understood;\n* Signed informed consent;\n* Affiliation with a social security scheme.\n\nExclusion Criteria:\n\n* Contraindication to rTMS (patient with conductive\u002Fsensitive material to magnetic fields implanted in the skull or less than 30 cm from the coil, implanted material controlled by physiological signals, history of epilepsy or unexplained seizures, drug treatment lowering the epileptic threshold, brain lesions in relation to the stimulation zone \\[of vascular, traumatic, tumoral, infectious or metabolic origin\\], sleep deprivation, alcoholism, treatment with electroconvulsive therapy in the previous month, uncontrolled intracranial hypertension,\n* Contraindication to MRI (ferromagnetic material not compatible with MRI including: intracerebral metal clip, pacemaker, insulin pump, intrathecal pump, metal prosthesis; severe claustrophobia)§ drug or psychoactive substance abuse\n* Presence of other pain more severe than that justifying inclusion\n* Patients under guardianship or deprived of liberty.\n* Pregnant or breast-feeding women\n* Patients participating in another research protocol involving a drug in the 30 days prior to inclusion.\n* Subject having already benefited from rTMS sessions in the past (to maintain the blind)",{"count":137,"type":22},120,[25],"This is a prospective clinical study evaluating the analgesic efficacy of a non-medicated treatment: repeated transcranial magnetic stimulation (rTMS) of the primary motor cortex in chronic migraine (\\> 7 headache days per month and failure of at least 3 drug treatments).\n\nTo this end, the study involves a double-blind, randomized, comparative experimental protocol against a sham control condition via 2 parallel groups comprising 60 patients each (N= 120 in total). Randomized block design with stratification by center and type of migraine (episodic or chronic).\n\n5 rTMS sessions will be performed, with one stimulation session every 2 weeks. One group will receive active stimulation at each session (high-frequency stimulation of the left primary motor cortex, 2000 pulses per session, 80% of resting motor threshold) and the other group placebo stimulation (sham).\n\nDepending on the randomization group, rTMS sessions will be carried out by trained experimenters in the investigating center where the patient has been included. The study is multicentric, with five centers, four of which are in the Auvergne-Rhône-Alpes region. Data will be centralized at the Clermont-Ferrand University Hospital, and statistical analysis will be carried out by the Clermont-Ferrand University Hospital's Clinical Research and Innovation Department. Principal difference analysis (active vs sham) performed in ITT; missing data processed by multiple imputation.",[33,141],"Migraine",[143],"rTMS neurostimulation","2025-07-16",{"date":146,"type":38},"2025-07-23",{"date":148,"type":22},"2025-07-31",{"date":150,"type":22},"2028-07-31",{"name":152,"class":79},"University Hospital, Clermont-Ferrand",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":171,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":46},"100589888","effects-of-repetitive-transcranial-magnetic-stimulations-in-patients-with-amphetamine-use-disorders-100589888","NCT06960265","Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders","A Pilot Study for the Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Amphetamine Use Disorders: Clinical Outcomes, Near InfraRed Spectroscopy, and Biomarkers","Inclusion Criteria:\n\n* Age ≥20 years.\n* Meeting DSM-5 criteria for substance use disorder made by a specialist in addiction psychiatry.\n* Fluency in Chinese.\n* Willingness and ability to comply with study requirements.\n* Good physical health determined by complete physical examination, and laboratory tests.\n* Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.\n* Trained psychiatrists will assess eligible patients using the structured clinical interview for the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) to determine the presence of any psychotic disorder.\n\nExclusion Criteria:\n\n* Evidence of an uncontrolled and\u002For clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.\n* Premorbid mental retardation.\n* Other major Axis-I Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnoses other than substance use disorder.\n* Pregnancy or nursing.\n* History of seizures or epilepsy.\n* History of neurological diseases or traumatic brain injury.\n* Suicidal attempts or risks during screening or study period.\n* Presence of prosthesis devices, e.g. pace-makers, cochlear prosthesis, neuro- stimulators, magnetic cochlear prosthesis, intraocular metallic fragments.","20 Years",{"count":57,"type":22},[25],"Amphetamine Use Disorder (AUD) is a major public health issue in Taiwan, where it is the most commonly abused illegal drug. There are currently no effective approved medications to treat it, which makes finding new treatment options urgent. Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation method, has shown promise in reducing cravings and drug use in people with addiction, but its effects on AUD are not well studied.\n\nTo explore this, the investigators plan to conduct a double-blind, sham-controlled study with 20 people diagnosed with AUD. Half will receive real rTMS treatment, and half will receive a placebo-like sham treatment. The treatment targets a specific brain area (the left dorsolateral prefrontal cortex) and will be given 10 times over two weeks.\n\nThe investigators will assess the effectiveness of rTMS by tracking drug cravings, urine test results, and side effects with follow-up over 12 weeks. The investigators also include brain imaging using near-infrared spectroscopy (NIRS) after the treatment.\n\nThe study aims to better understand how rTMS might help reduce amphetamine cravings and improve outcomes, potentially leading to new treatment options for AUD.",[165,166,167,168,169,170,33],"Amphetamine Use Disorders","Amphetamine Use Disorder","Amphetamine Dependence","Amphetamine Abuse","NIRS","rTMS",[172,173,169],"amphetamine","rtms","2025-04-28",{"date":176,"type":38},"2025-05-07",{"date":178,"type":22},"2025-05-15",{"date":180,"type":22},"2025-12-31",{"name":182,"class":79},"TsaoTun Psychiatric Center, Department of Health, Taiwan",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":46},"100421890","effectiveness-of-high-frequency-rtms-in-reducing-alcohol-consumption-in-non-abstinent-patients-with-an-alcohol-use-disorder-100421890","NCT04773691","Effectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder","Effectiveness of High-frequency rTMS in Reducing Alcohol Consumption in Non-abstinent Patients With an Alcohol Use Disorder: A Multicentre Randomised Controlled Study","ALCOSTIM","Inclusion Criteria:\n\n* a person who has given his or her free, written and informed consent\n* adult patient\n* patient with mild to severe alcohol use disorder according to DSM-5 criteria\n* voluntary patient to reduce alcohol consumption\n* patient who has already made at least one attempt at alcohol withdrawal (failure or relapse), or at reducing consumption\n\nExclusion Criteria:\n\n* person who is not affiliated to or not a beneficiary of national health insurance\n* person subject to a legal protection measure (curatorship, guardianship)\n* person subject to a legal safeguard measure\n* pregnant, parturient or breastfeeding women\n* adult unable to express consent\n* patient of childbearing age with a positive pregnancy test at inclusion\n* patient with an exhaled alcohol level \\> 0 milligrams\u002Flitre inclusive\n* patient with heavy alcohol consumption \\\u003C 6 days in the 4 weeks prior to inclusion (European Medicine Agency, 2010; one day with alcohol consumption of 60g or more for men and 40g for women)\n* patient with an average alcohol consumption below the WHO average risk level in the 4 weeks prior to inclusion (WHO, 2000, less than or equal to 40g\u002Fday for men and 40g for women)\n* patient being abstinent more than 5 days before inclusion\n* patient with a CIWA (Clinical Institute Withdrawal Evaluation: assessment of the severity of alcohol withdrawal) score greater than or equal to 10 at inclusion\n* Patient with concomitant treatment with disulfiram, acamprosate, topiramate, baclofen, naltrexone, and nalmefen (\\\u003C 1 month)\n* Patient with a history or presence of pre-delirium tremens or delirium tremens\n* Patient with a substance use disorder (DSM-5 criteria) with psychoactive substances other than tobacco and alcohol.\n* Patient with acute psychiatric disorders requiring hospitalization and\u002For immediate adjustment of psychotropic medication\n* Patient with severe depression, defined by a score of 24 or more on the Hamilton Depression Scale (HAM-D).\n* Patient who has had a recent change (\\\u003C 1 month) in the prescription of psychotropic treatment\n* Patient with severe and\u002For chronic psychiatric disorders, including schizophrenia, paranoia and bipolar disorders type I and II\n* Patient with severe heart, kidney, liver or lung failure or other condition that the doctor believes could compromise the patient's participation in the study.\n* Patient with a contraindication to the practice of rTMS; personal history of seizure, pacemaker, neurosurgical clips, carotid or aortic clips, heart valves, hearing aid, ventricular bypass valve, sutures with wires or staples, foreign bodies in the eye, shrapnel, other prosthesis or cephalic ferromagnetic material.\n* Patient simultaneously participating in another therapeutic trial\n* Patient employed by the investigator or trial site\n* Patient who, according to the investigator, is unable to complete a consumption diary and follow up visits for 6 months\n* Patient refusing to sign the \"safety contract \"\\* specific to the study",{"count":192,"type":22},144,[25],"The fight against alcoholism is a public health priority. Around 15 million Europeans and 10 million North Americans are alcohol dependent. Worldwide, 1 death out of 25 is thought to be attributed to alcohol. In France, the latest published data on alcohol-related mortality indicates that there were 49,000 alcohol-related deaths in 2009. Alcohol is thought to be the leading cause of hospitalisation for French people, and its social cost is estimated at 37.4 billion euros.\n\nHowever, few patients with an alcohol use disorder are treated: less than 8% in Europe and less than 10.5% in the USA receive appropriate treatment for their alcohol problem. This low rate of treatment is mainly due to the fact that these patients are not ready to stop drinking. They are therefore not attracted by the goal of abstinence that is required by most current therapies and drug treatments. The arrival of new treatments aimed at reducing consumption (rather than abstinence) should make treatment more attractive. To date, nalmefen is the only treatment marketed for this indication. Baclofen should be marketed in 2020, but with restrictive prescription criteria.\n\nIn this new strategy to reduce consumption, brain stimulation could play a predominant role as an alternative or complementary therapy. Indeed, functional brain imaging techniques have made it possible to visualise the cortical regions involved in craving, in particular the dorsolateral prefrontal cortex (DLPFC). Craving, i.e. the irrepressible desire to consume, is often at the origin of consumption and relapse. Stimulation of the dorsolateral prefrontal cortex with non-invasive cerebral stimulation techniques, such as repeated transcranial magnetic stimulation (rTMS), has provided encouraging results for the reduction of cravings in all addictive behaviours (alcohol, tobacco, cocaine, food). Furthermore, stimulation of the DLPFC seems to modulate decision-making processes: it may thus reduce impulsivity and strengthen inhibitory control, leading to a reduction in substance use.\n\nThe hypothesis to be tested is that repeated transcranial magnetic stimulation allows a reduction in alcohol consumption in patients with an alcohol use disorder.",[196,33],"Alcoholism","2025-04-15",{"date":199,"type":38},"2025-04-17",{"date":201,"type":38},"2021-03-01",{"date":76,"type":22},{"name":204,"class":79},"Centre Hospitalier Universitaire Dijon",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":211,"maxAge":86,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":46},"100577317","prospective-exploratory-study-on-rtms-for-migraine-under-the-guidance-of-meg-100577317","NCT06796725","Prospective Exploratory Study on rTMS for Migraine Under the Guidance of MEG","Inclusion Criteria:\n\n* Complies with specific disease diagnosis: A. Headaches that meet the criteria of B and C (headaches that meet the characteristics of tension headaches or migraines) should occur at least 15 days per month and last for at least 3 months; B. Headaches that meet the criteria of 1.1 migraine without aura diagnosis B-D or 1.2 migraine with aura B and C occurring at least 5 times; C. Headache meets any of the following criteria and occurs for more than 8 days per month, lasting for more than 3 months: ①1.1 C and D of migraine without aura②1.2 B and C of migraine with aura③ The migraine attack perceived by the patient can be relieved by taking triptan or ergot, which cannot be better explained by other diagnoses in ICHD-3.\n* Must be able to swallow tablets\n* Signed and dated informed consent form Promise to comply with research procedures and cooperate in implementing the entire research process\n\nExclusion Criteria:\n\n* Age under 15 years old; Accompanied by optic disc edema, focal symptoms and signs of the nervous system (except for typical visual and sensory precursors) or cognitive impairment; Sudden and rapidly peaking severe headaches (thunderous headaches)\n* Accompanied by fever; New onset headaches in adults, especially after the age of 50; Headaches in patients with high coagulation risk\n* New headache in patients with tumor or AIDS history; Headaches related to changes in body position;\n* History of epileptic seizures","15 Years",{"count":213,"type":22},60,[25],"Using magnetoencephalography to locate and regulate targets in migraine patients, repeating transcranial magnetic stimulation to physically regulate targets, and evaluating the safety and effectiveness of this treatment method through headache related scales. Using whole genome data and scale scores for correlation analysis, and conducting randomized controls with traditional drugs to explore new approaches for migraine.",[217,33],"Migraine Disorders, Brain",[141,219,170,220],"MEG","RCT","2025-02-08",{"date":223,"type":38},"2025-02-11",{"date":225,"type":38},"2025-02-06",{"date":227,"type":22},"2026-06-30",{"name":229,"class":79},"Ruijin Hospital"]